FDA approves label expansion for Vyvgart, Vyvgart Hytrulo for generalized myasthenia gravis

The U.S. Food and Drug Administration has approved a label expansion for Vyvgart (efgartigimod alfa-fcab) and Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) for the treatment of adult patients with (gMG). The expanded approval was granted to argenx.